Table 4 Haematological toxicity

From: Phase II study of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with stage IIIb and IV non-small-cell lung cancer

 

First course

Second course

Third course

Leucopenia

   

 Median nadir (× 103 mm−3)

2.7

2.9

1.9

 Range

0.3–5.5

0.6–5.1

0.5–5.1

 Day nadir

15.0

15.0

15.0

Neutropenia

   

 Median nadir (× 103 mm−3)

1.3

1.5

0.8

 Range

0.0–3.8

0.1–3.7

0.0–3.1

 Day nadir

15.0

15.0

15.0

Thrombocytopenia

   

 Median nadir (× 103 mm−3)

12.6

10.9

6.4

 Range

2.9–27.0

2.5–21.3

0.9–19.9

 Day nadir

15.0

15.0

15.0

No. of patients transfused

1

0

7

Anaemia

   

 Median nadir (g dl−1)

10.0

9.1

8.3

 Range

7.7–12.5

7.3–11.6

7.0–11.1

 No. of patients transfused

5

10

20

Back to article page